Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
:URGN
URGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.42 - $21.02
Previous CloseN/A
Volume157.75K
Average Volume (3M)1.10M
Market Cap
$869.77M
Enterprise Value$623.47M
Total Cash (Recent Filing)$156.95M
Total Debt (Recent Filing)$125.92M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 17, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding46,264,133
10 Day Avg. Volume1,144,211
30 Day Avg. Volume1,099,808
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue6.62
Enterprise Value/Gross Profit7.47
Enterprise Value/Ebitda-5.30
Forecast
1Y Price Target
$32.75Price Target Upside73.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Clinical DataZUSDURI long-term clinical data appear compelling with a 78% complete response for patients at three months, and 79% of those patients remained event-free 12 months later.
Market PotentialZUSDURI could reach blockbuster status given the much larger size of the NMIBC target market and the fact that ZUSDURI is currently the only pharmacotherapy approved to treat recurrent LG-IR-NMIBC.
Product ApprovalZUSDURI has been designed for potent tumor ablation, offering a new alternative for recurrent LG-IR-NMIBC patients who often endure multiple resections under general anesthesia.
Bears Say
Financial PerformanceRevenue and earnings miss moderately—lowering price target based on revised sales ramp trajectory.
Urogen Pharma News
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $3.42 and its highest was $21.02 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $869.77M.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Nov 17, 2025 which is in 71 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Aug 07, 2025. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.865 by -$0.185.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.64.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 46,264,133 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.865. Following the earnings report the stock price went down -7.096%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
Urogen Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.75 (73.46% Upside)
$32.75 (73.46% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $176.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.50%
12-Months-Change
Fundamentals
Return on Equity
-452.20%
Trailing 12-Months
Asset Growth
-25.95%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
URGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements, including FDA approval of ZUSDURI and strong revenue growth for JELMYTO. However, these were balanced by challenges such as reimbursement issues for ZUSDURI and increased operating expenses, resulting in a larger net loss.View all URGN earnings summariesURGN Stock 12 Month Forecast
Average Price Target
$32.75
▲(73.46% Upside)
Technical Analysis
Niagen Bioscience
―
Savara
―
Arvinas Holding Company
―
Bicycle Therapeutics
―
Opthea Limited Sponsored ADR
―
Ownership Overview
1.20% Insiders
2.47% Mutual Funds
49.78% Other Institutional Investors
41.50% Public Companies and Individual Investors